title: Treating older adults with schizophrenia: challenges and opportunities.
abstract: Schizophrenia affects people of all age groups. Treatment plans for older adults with schizophrenia must consider the effects of age on the course of the illness as well as on the response to antipsychotics and to psychosocial interventions. Positive symptoms of schizophrenia tend to become less severe, substance abuse becomes less common, and mental health functioning often improves. Hospitalizations are more likely to be due to physical problems rather than psychotic relapses. Physical comorbidity is a rule, however, and older age is a risk factor for most side effects of antipsychotics, including metabolic syndrome and movement disorders. We recently reported high rates of adverse events and medication discontinuation along with limited effectiveness of commonly used atypical antipsychotics in older adults. Psychosocial interventions such as cognitive behavioral social skills training are efficacious in improving functioning in older adults with schizophrenia. In formulating treatment plans for this population, a balanced approach combining cautious antipsychotic medication use with psychosocial interventions is recommended. Antipsychotic medications should generally be used in lower doses in older adults. Close monitoring for side effects and effectiveness of the medications and a watchful eye on their risk:benefit ratio are critical. In a minority of patients it may be possible to discontinue medications. Sustained remission of schizophrenia after decades of illness is not rare, especially in persons who receive appropriate treatment and psychosocial support-there can be light at the end of a long tunnel.
authors.affiliation: Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA. djeste@ucsd.edu
authors.forename: Dilip V
authors.initials: DV
authors.lastname: Jeste
authors.forename: Jeanne E
authors.initials: JE
authors.lastname: Maglione
mesh_terms: D014150:Antipsychotic Agents / Q000008:administration & dosage*; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents
keywords: aging; antipsychotics; cognition; psychosis; psychosocial treatments; schizophrenia
references.citation: Drugs Aging. 1998 Feb;12(2):115-27
references.pmid: 9509290
references.citation: Br J Clin Pharmacol. 1980 Apr;9(4):432-4
references.pmid: 7378262
references.citation: Schizophr Res. 2009 Mar;108(1-3):207-13
references.pmid: 19168328
references.citation: Am J Psychiatry. 2000 Feb;157(2):172-8
references.pmid: 10671383
references.citation: J Consult Clin Psychol. 2010 Aug;78(4):561-73
references.pmid: 20658812
references.citation: J Nerv Ment Dis. 2010 Oct;198(10):715-21
references.pmid: 20921861
references.citation: Schizophr Bull. 2006 Apr;32(2):288-96
references.pmid: 16254059
references.citation: Am J Geriatr Psychiatry. 2009 Mar;17(3):255-63
references.pmid: 19225277
references.citation: J Clin Psychiatry. 2013 Jan;74(1):10-8
references.pmid: 23218100
references.citation: Am J Psychiatry. 2004 Aug;161(8):1490-3
references.pmid: 15285980
references.citation: Schizophr Res. 2006 Sep;86(1-3):291-9
references.pmid: 16814526
references.citation: Lancet. 2009 Aug 22;374(9690):620-7
references.pmid: 19595447
references.citation: Schizophr Bull. 2011 May;37(3):451-5
references.pmid: 21505111
references.citation: Arch Gen Psychiatry. 2007 Oct;64(10):1123-31
references.pmid: 17909124
references.citation: J Clin Psychiatry. 2007 May;68(5):730-7
references.pmid: 17503982